Boston Scientific Corp (BSX)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Boston Scientific Corp.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 2 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 46.70 $ — 6% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 37.6% above the current price.
- Consensus
- Strong Sell
- Analyst Ratings
- 34
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 3.31 | 3.28 – 3.37 | 21,404 | 8.0% | 23 |
| 12/31/2027 | 3.48 | 3.32 – 3.90 | 22,440 | 5.3% | 27 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | 0.38 | 11.30 | 4,561 | 22.40 | 12.40 | 1,456 | 1,163 |
| 2025: Q1 | 0.45 | 35.40 | 4,663 | 20.90 | 14.50 | 541 | 354 |
| 2025: Q2 | 0.53 | 143.30 | 5,061 | 22.80 | 15.70 | 1,286 | 1,096 |
| 2025: Q3 | 0.50 | 60.10 | 5,065 | 20.30 | 14.90 | 1,343 | 1,162 |
| 2025: Q4 | 0.45 | 17.60 | 5,286 | 15.90 | 12.60 | 1,364 | 1,013 |
| 2026: Q1 | 0.89 | 98.10 | 5,203 | 11.60 | 25.70 | 348 | 171 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 8,386 | 1,236 | 347 | 0.25 | 972 | 6,733 | 18,096 |
| 2017 | 9,048 | 1,525 | 104 | 0.07 | 1,426 | 7,011 | 19,041 |
| 2018 | 9,823 | 1,737 | 1,671 | 1.19 | 310 | 8,725 | 20,998 |
| 2019 | 10,735 | 1,712 | 4,700 | 3.33 | 1,836 | 13,877 | 30,565 |
| 2020 | 9,913 | 601 | -82 | -0.06 | 1,508 | 15,327 | 30,778 |
| 2021 | 11,888 | 1,922 | 1,040 | 0.73 | 1,870 | 16,623 | 32,230 |
| 2022 | 12,682 | 1,824 | 698 | 0.48 | 1,526 | 17,574 | 32,470 |
| 2023 | 14,240 | 2,181 | 1,593 | 1.09 | 2,503 | 19,282 | 35,136 |
| 2024 | 16,747 | 2,635 | 1,854 | 1.25 | 3,435 | 21,770 | 39,395 |
| 2025 | 20,074 | 3,971 | 2,886 | 1.93 | 4,534 | 24,233 | 43,673 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Boston Scientific Corporation entwickelt, fertigt und vermarktet weltweit Medizinprodukte für diverse interventionelle Fachgebiete. Das Unternehmen ist in zwei Segmenten tätig: MedSurg und Cardiovascular.
| CEO Insider Trades (12 Mo.) | selling own stock |
|---|---|
| Employees | 59,000 |
| Headquarters | Marlborough, MA |
| Address | 300 Boston Scientific Way, 01752-1234 Marlborough, United States |
| Phone | 508 683 4000 |
| Website | bostonscientific.com |
| IPO Date | 18. May 1992 |
| ISIN | US1011371077 |
| Stock Split | 2:1 on 11/06/2003 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Michael F. Mahoney | Chairman, President & CEO | 1965 |
| Jonathan R. Monson | Executive VP & CFO | 1974 |
| Vance R. Brown J.D. | EVP, General Counsel & Corporate Secretary | 1970 |
| Joseph M. Fitzgerald | Executive VP & Group President of Cardiovascular | 1964 |
| Arthur Crosswell Butcher | Executive VP and Group President of MedSurg & Asia Pacific | 1971 |
| Paudie O'Connor | Executive Vice President of Global Operations | 1968 |
| Emily M. Woodworth | Senior VP, Global Controller & Chief Accounting Officer | 1978 |
| Adam Smith | General Manager of Global Sales & Marketing | – |
| Miriam O'sullivan | Senior VP & Chief Human Resources Officer | 1981 |
| Brenda Becker | Senior Vice President of Global Government Affairs | 1960 |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.